Scandion Oncology A/S (“Scandion Oncology”) reports that the next evaluable colorectal cancer patient at the 8 weeks CT-scanning shows stable disease in the patients liver metastases, which are used to measure disease activity but a new metastatic lesion has appeared in the lung of the patient. According to the clinical protocol the patient will discontinue protocol treatment.
In the first cohort of chemotherapy resistant colorectal cancer patients treated with SCO-101 and chemotherapy (FOLFIRI) we now have evaluated treatment effects on tumor size in the first two patients. One patient has obtained stable disease, according to RECIST version 1.1 at 8 weeks after starting the treatment. The patient with new metastatic lesion in the lung will now discontinue protocol treatment although the liver metastases show stable disease.
The patients included have late stage metastatic colorectal cancer, for whom no additional treatment is available. All patients have previously had benefit with FOLFIRI (chemotherapy) treatment but subsequently, their cancer started to grow or showed new metastatic lesions despite the continued FOLFIRI treatment. The patients were then offered to be enrolled in the Scandion Oncology clinical phase II trial. The primary objective of the first part of the trial is to establish the safety, tolerability and Maximum Tolerated Dose of SCO-101 in combination with FOLFIRI. Moreover, this part also provides the first data on efficacy of SCO-101 when combined with FOLFIRI.
CEO Nils Brünner says “I am satisfied with the progress we have had in our first part of the clinical colorectal cancer study. Even with few patients, the results showing stable disease in the first patient and stable liver metastases but a new lesion in the next evaluable patient are still encouraging. We have many patients still to be included, and I am looking forward to follow these patients. Scandion Oncology is learning a lot from the first patients in the dose finding part of the study, information that is used to establish the recommended dose of SCO-101 and chemotherapy for future patients/trials. We are now adding additional patients to cohort 1 to learn even more about the interactions between SCO-101 and FOLFIRI chemotherapy. We have decided that the next news release will be when part 1 has been finalized”.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on August 20, 2020.
Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: http://www.scandiononcology.com.